Comparative Pharmacology
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus MPI KRYPTON 81M GENERATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI INDIUM DTPA IN 111 versus MPI KRYPTON 81M GENERATOR.
MPI INDIUM DTPA IN 111 vs MPI KRYPTON 81M GENERATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Krypton-81m (81mKr) is a short-lived radionuclide that decays by isomeric transition emitting gamma rays (190 keV). When inhaled, it distributes in the lungs according to regional ventilation. Imaging is performed using a gamma camera to assess pulmonary ventilation. The generator produces 81mKr from its parent rubidium-81 (81Rb).
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
Intravenous infusion of krypton-81m gas in oxygen, typically 400-800 MBq (10-20 mCi) per study, administered via generator elution with a flow rate of 500-1000 mL/min. Adult dose per lung ventilation study: 100-400 MBq (2.7-10.8 mCi) inhaled in a single breath or continuous breathing for 1-2 minutes.
None Documented
None Documented
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Physical half-life of krypton-81m: 13.1 seconds; biological half-life is negligible as it is inert gas eliminated via exhalation.
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Renal: ~100% (krypton-81m is exhaled and decay products are excreted renally; as a gas, the primary elimination is via exhalation, with the decay product rubidium-81 cleared renally).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical